 Sierra Oncology NASDAQ: SRRA shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC LON: GSK for 55 a share in cash. That represents a total equity value of 1.9 billion, attributed mainly to SRRAs Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways. 